Evidence Snapshot

Parathyroid hormone/parathyroid hormone-related peptide receptor

CHEMBL1793 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:19Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1793

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Parathyroid hormone/parathyroid hormone-related peptide receptor as ChEMBL target CHEMBL1793, mapped to UniProt Q03431. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Parathyroid hormone/parathyroid hormone-related peptide receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1793

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q03431

Parathyroid hormone/parathyroid hormone-related peptide receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Parathyroid hormone/parathyroid hormone-related peptide receptor matters

As of 2026-09-13

Parathyroid hormone/parathyroid hormone-related peptide receptor is reviewed as Parathyroid hormone/parathyroid hormone-related peptide receptor (UniProt Q03431); Parathyroid hormone/parathyroid hormone-related peptide receptor shows approved-linked disease relevance led by hypoparathyroidism. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 46854 compounds, and 57 assays, with lead potency reaching pChEMBL 10.2.

Protein context

Parathyroid hormone/parathyroid hormone-related peptide receptor

Parathyroid hormone/parathyroid hormone-related peptide receptor Sequence length is 593 aa.

Review this target as Parathyroid hormone/parathyroid hormone-related peptide receptor, mapped to UniProt Q03431. Sequence length is 593 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q03431 Protein

Disease context

hypoparathyroidism

Parathyroid hormone/parathyroid hormone-related peptide receptor shows approved-linked disease relevance led by hypoparathyroidism. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PALOPEGTERIPARATIDE, PARATHYROID HORMONE, TERIPARATIDE.

Start review with hypoparathyroidism because it currently carries approved-linked support. Linked drugs include PALOPEGTERIPARATIDE, PARATHYROID HORMONE, TERIPARATIDE, TERIPARATIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 4 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 46854 compounds, and 57 assays for this target. The dominant activity type is EC50. CHEMBL526530 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL526530 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine

2 approved pChEMBL 10.2

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Parathyroid hormone/parathyroid hormone-related peptide receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q03431, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hypoparathyroidism is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

46854

Total Compounds

Total Assays

Approved Drugs

IC50: 63.0, KI: 26.0, EC50: 91.0, KD: 8.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL526530	10.2	EC50	—
No preferred name CHEMBL4098420	10.2	EC50	—
No preferred name CHEMBL4080397	10.2	EC50	—
No preferred name CHEMBL4060034	10.1	EC50	—
No preferred name CHEMBL525610	10.1	IC50	Approved

Approved Drugs

Structure	Compound	First Approval
	TERIPARATIDE CHEMBL525610	2002

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:19Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1793